Compare ORIO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | LPCN |
|---|---|---|
| Founded | N/A | 1997 |
| Country | Canada | United States |
| Employees | 188 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 19.1M |
| IPO Year | N/A | 2011 |
| Metric | ORIO | LPCN |
|---|---|---|
| Price | $0.85 | $2.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.2K | ★ 103.2K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,976,677.00 |
| Revenue This Year | $74.52 | N/A |
| Revenue Next Year | $5.07 | $92.00 |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $1.81 |
| 52 Week High | $1.40 | $12.37 |
| Indicator | ORIO | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 60.16 |
| Support Level | $0.84 | $2.59 |
| Resistance Level | $0.98 | $2.67 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 25.51 | 89.30 |
Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.